Pharmaceutical Executive
The third quarter reports are in, and Pfizer's profits are up but sales are down. The company is compensating for looming patent expirations with layoffs and restructuring; is it enough to boost sales?
Pharmaceutical Executive-10-22-2009
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
